Antiatherogenic properties of fibrates

被引：7

作者：

Barter, PJ ^{[1
]}

机构：

[1] Heart Res Inst, Sydney, NSW, Australia

来源：

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2005年 / 25卷 / 06期

关键词：

D O I：

10.1161/01.ATV.0000168895.21726.20

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

收藏

页码：1095 / 1096

页数：2

相关论文

共 15 条

[1] Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages [J].

Aiello, RJ ;

Brees, D ;

Bourassa, PA ;

Royer, L ;

Lindsey, S ;

Coskran, T ;

Haghpassand, M ;

Francone, OL .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2002, 22 (04) :630-637

[2] Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner [J].

Arakawa, R ;

Tamehiro, N ;

Nishimaki-Mogami, T ;

Ueda, K ;

Yokoyama, S .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (06) :1193-1197

[3] Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice [J].

Berthou, L ;

Duverger, N ;

Emmanuel, F ;

Langouet, S ;

Auwerx, J ;

Guillouzo, A ;

Fruchart, JC ;

Rubin, E ;

Denefle, P ;

Staels, B ;

Branellec, D .

JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (11) :2408-2416

[4] PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway [J].

Chinetti, G ;

Lestavel, S ;

Bocher, V ;

Remaley, AT ;

Neve, B ;

Torra, IP ;

Teissier, E ;

Minnich, A ;

Jaye, M ;

Duverger, N ;

Brewer, HB ;

Fruchart, JC ;

Clavey, V ;

Staels, B .

NATURE MEDICINE, 2001, 7 (01) :53-58

[5] Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients [J].

Ericsson, CG ;

Hamsten, A ;

Nilsson, J ;

Grip, L ;

Svane, B ;

deFaire, U .

LANCET, 1996, 347 (9005) :849-853

[6]

Frick MH, 1997, CIRCULATION, V96, P2137

[7] HELSINKI HEART-STUDY - PRIMARY-PREVENTION TRIAL WITH GEMFIBROZIL IN MIDDLE-AGED MEN WITH DYSLIPIDEMIA - SAFETY OF TREATMENT, CHANGES IN RISK-FACTORS, AND INCIDENCE OF CORONARY HEART-DISEASE [J].

FRICK, MH ;

ELO, O ;

HAAPA, K ;

HEINONEN, OP ;

HEINSALMI, P ;

HELO, P ;

HUTTUNEN, JK ;

KAITANIEMI, P ;

KOSKINEN, P ;

MANNINEN, V ;

MAENPAA, H ;

MALKONEN, M ;

MANTTARI, M ;

NOROLA, S ;

PASTERNACK, A ;

PIKKARAINEN, J ;

ROMO, M ;

SJOBLOM, T ;

NIKKILA, EA .

NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (20) :1237-1245

[8] Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and β [J].

Li, AC ;

Binder, CJ ;

Gutierrez, A ;

Brown, KK ;

Plotkin, CR ;

Pattison, JW ;

Valledor, AF ;

Davis, RA ;

Willson, TM ;

Witztum, JL ;

Palinski, W ;

Glass, CK .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (11) :1564-1576

[9] Relation of gemfibrozil treatment and lipid levels with major coronary events - VA-HIT: A randomized controlled trial [J].

Robins, SJ ;

Collins, D ;

Wittes, JT ;

Papademetriou, V ;

Deedwania, PC ;

Schaefer, EJ ;

McNamara, JR ;

Kashyap, ML ;

Hershman, JM ;

Wexler, LF ;

Rubins, HB .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (12) :1585-1591

[10] Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol [J].

Rubins, HB ;

Robins, SJ ;

Collins, D ;

Fye, CL ;

Anderson, JW ;

Elam, MB ;

Faas, FH ;

Linares, E ;

Schaefer, EJ ;

Schectman, G ;

Wilt, TJ ;

Wittes, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (06) :410-418